Larotrectinib
Information
- Drug Name
- Larotrectinib
- Description
- Entry(CIViC)
- 23
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung adenocarcinoma | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24162815 | Detail |
| cancer | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26603524 | Detail |
| sarcoma | NTRK1 LMNA-NTRK1 | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26216294 | Detail |
| sarcoma | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26216294 | Detail |
| sarcoma | NTRK2 NTRK2-STRN fusion | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29606586 | Detail |
| childhood fibrosarcoma | NTRK3 ETV6-NTRK3 | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 29606586 | Detail |
| sarcoma | NTRK1 LMNA-NTRK1 | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29606586 | Detail |
| sarcoma | NTRK1 TMP3-NTRK1 NTRK1 TMP3-NTRK1 | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 29606586 | Detail |
| sarcoma | NTRK1 PDE4DIP-NTRK1 | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29606586 | Detail |
| childhood fibrosarcoma | NTRK1 SQSTM1-NTRK1 | C |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 29606586 | Detail |
| melanoma | NTRK1 NTRK1-TRIM63 | E |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 29683819 | Detail |
| melanoma | NTRK1 NTRK1-DDR2 | E |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 29683819 | Detail |
| melanoma | NTRK1 NTRK1-GON4L | E |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 29683819 | Detail |
| acute myeloid leukemia | NTRK2 ETV6-NTRK2 | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29920189 | Detail |
| congenital fibrosarcoma | NTRK3 ETV6-NTRK3 FUSION | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 27093299 | Detail |
| breast secretory carcinoma | NTRK3 ETV6-NTRK3 | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 29623306 | Detail |
| cancer | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29466156 | Detail |
| cancer | NTRK3 NTRK3 FUSIONS NTRK3 NTRK3 FUSIONS | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29466156 | Detail |
| cancer | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29606586 | Detail |
| Pediatric B-lymphoblastic Leukemia | NTRK3 ETV6-NTRK3 | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29880614 | Detail |
| cancer | NTRK3 ETV6-NTRK3 | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 30624546 | Detail |
| B-cell adult acute lymphocytic leukemia | NTRK3 ETV6-NTRK3 | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 31905241 | Detail |
| colorectal cancer | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 26716414 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Two patients were found to harbor gene fusions mai... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| Results from a phase I study show that the TRK inh... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| LOXO-101 is an orally administered inhibitor of th... | NTRK1 | NTRK1 LMNA-NTRK1 | Sensitivity | true | CIViC Evidence | detail |
| LOXO-101 is an orally administered inhibitor of th... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| One Patient with soft tissue sarcoma and a NTRK2-S... | NTRK2 | NTRK2 NTRK2-STRN fusion | Sensitivity | true | CIViC Evidence | detail |
| Four out of six patients with infantile fibrosarco... | NTRK3 | NTRK3 ETV6-NTRK3 | Sensitivity | true | CIViC Evidence | detail |
| One Patient with soft tissue sarcoma and a NTRK1-L... | NTRK1 | NTRK1 LMNA-NTRK1 | Sensitivity | true | CIViC Evidence | detail |
| Four patients with infantile fibrosarcoma and soft... | NTRK1 | NTRK1 TMP3-NTRK1 NTRK1 TMP3-NTRK1 | Sensitivity | true | CIViC Evidence | detail |
| One Patient with soft tissue sarcoma and a NTRK1-P... | NTRK1 | NTRK1 PDE4DIP-NTRK1 | Sensitivity | true | CIViC Evidence | detail |
| One patient with infantile fibrosarcoma and a NTRK... | NTRK1 | NTRK1 SQSTM1-NTRK1 | Sensitivity | true | CIViC Evidence | detail |
| In this study we report that nonspitzoid metastasi... | NTRK1 | NTRK1 NTRK1-TRIM63 | Sensitivity | true | CIViC Evidence | detail |
| In this study we report that nonspitzoid metastasi... | NTRK1 | NTRK1 NTRK1-DDR2 | Sensitivity | true | CIViC Evidence | detail |
| In this study we report that nonspitzoid metastasi... | NTRK1 | NTRK1 NTRK1-GON4L | Sensitivity | true | CIViC Evidence | detail |
| Rearrangements involving the neurotrophic receptor... | NTRK2 | NTRK2 ETV6-NTRK2 | Sensitivity | true | CIViC Evidence | detail |
| Nagasubramanian et al reports on a case of refract... | NTRK3 | NTRK3 ETV6-NTRK3 FUSION | Sensitivity | true | CIViC Evidence | detail |
| Shukla et al report on a remarkable case study of ... | NTRK3 | NTRK3 ETV6-NTRK3 | Sensitivity | true | CIViC Evidence | detail |
| This was a Phase 1/2 study of 55 patients from 4 m... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| This was a Phase 1/2 study of 55 patients from 4 m... | NTRK3 | NTRK3 NTRK3 FUSIONS NTRK3 NTRK3 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| In a Phase 1/2 study involving 15 pediatric patien... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| In this manuscript, the authors describe the first... | NTRK3 | NTRK3 ETV6-NTRK3 | Sensitivity | true | CIViC Evidence | detail |
| In this phase 1 dose-escalation study seventy pati... | NTRK3 | NTRK3 ETV6-NTRK3 | Sensitivity | true | CIViC Evidence | detail |
| 61-year-old man is diagnosed with B-ALL. While an... | NTRK3 | NTRK3 ETV6-NTRK3 | Sensitivity | true | CIViC Evidence | detail |
| NTRK1 fusions (one LMNA-NTRK1 and two TPM3-NTRK1) ... | NTRK1 | NTRK1 NTRK1 FUSIONS NTRK1 NTRK1 FUSIONS | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT06390852 | Active, not recruiting | Phase 2 | Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) | March 12, 2017 | March 24, 2025 |
| NCT02693535 | Recruiting | Phase 2 | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | March 14, 2016 | December 31, 2025 |
| NCT04655404 | Recruiting | Early Phase 1 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | April 8, 2021 | December 1, 2025 |
| NCT05725200 | Recruiting | Phase 2 | Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer | September 27, 2022 | December 31, 2040 |